clinical-bacteria-resistance-103.html
DANMAP 2015 3D
104 / 144
danmap
2015
104 resistance
in human clinical bacteria 8. highlights: danmap 2015 is the first danmap report with data on resistance in blood iso- lates referred from all danish dcm, thereby covering all of the danish population. e. coli from bloodstream infections is the only clinically important human bacteria, where resistance has been continuously reported through all 20 years. in 2015, no significant changes in resistance were reported for e. coli isolates
obtained from bloodstream infec- tions: resistance to ciprofloxacin was 12%, cefuroxime 9%, 3rd generation cephalosporins 7 % and gentamicin 9%, respectively. one carbapenemase-resistant and four intermediary resistant e. coli isolates were reported. during the last decade steady increases in resistance occurred for e. coli from bloodstream infections, most pronounced for 2006 to 2011, since levelling off. over the last twenty years the resistance to ampicillin increased from 35% to 45% for e. coli , also here, the most pronounced changes happened from 2006 to 2011. during the last twenty years, the resistance levels have continuously increased for e. coli ob- tained from urinary tract infections from hospitalized patients. whereas decreases for most antimicrobial classes were observed for e. coli isolates obtained from patients with unitary tract infections from primary healthcare. for k. pneumoniae isolates obtained from bloodstream infections in 2015, gentamicin resistance decreased to 2.5% (4.6% in 2014). resistance to most antimicrobials has steadily decreased since 2009. in 2015, 11% of the k. pneumoniae isolates were resistant to cefu- roxime, 8% to 3rd generation cephalosporins and 6% to ciprofloxacin. the only antimicrobial with increasing resistance since registration was begun in 2009 was piperacillin-tazobac- tam. in 2015, 8% of the k. pneumoniae isolates from blood were resistant to piperacillin- tazobactam. none carbapenem-resistant and two intermediary resistant k. pneumoniae isolates were reported in 2015. for k. pneumoniae isolates obtained from urins from patients with urinary tract infections resistance to ciprofloxacin decreased from 8% to 6% in urinary isolates from hospitals and from 7% to 5% in urinary isolates from primary health care. in 2015, whole-genome sequencing was performed on 275 esbl- and/or carbapenemase-pro- ducing e. coli isolates from blood and on additional 59 carbapenemase-producing enterobacte- riaceae (cpe), 19 carbapenemase-producing a. baumannii and nine carbapenemase-producing pseudomonas spp. (textboxes 8.1 and 8.2). the occurrence of these carbapenemase-produc- ing bacteria in denmark is increasing, a trend worrisome to patients and clinicians. especially the spread of cpe worries due to their ability to be carried in the gut for a long time. staphylococcus aureus bacteremia?s accounted for 1,973 cases, the third year in a row where the number of cases was higher than the previous year. twenty-nine (1.5%) of these were caused by mrsa and three of them by mrsa cc398. the mortality was 23% for the methicillin susceptible cases and 24% for the cases with mrsa. resistance towards eryth- romycin, clindamycin, fusidic acid and norfloxacin has been steadily increasing in the last decade. in 2015 it was 7%, 7%, 16% and 6%, respectively. for the first time in recent years, the number of new mrsa cases (colonized or infected patients) stabilized with 2,971 cases compared to 2,965 cases in 2014. 8. resistance in clinical bacteria from humans and animals
isolates-2015-blood-105.html
